Modulation of voltage-gated channel currents by harmaline and harmane

British Journal of Pharmacology

Volumn 144, Issue 1, 2005, Pages 52-58

  Splettstoesser, Frank ^a   Bonnet, Udo ^a   Wiemann, Martin ^a   Bingmann, Dieter ^a   Büsselberg, Dietrich ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Dorsal root ganglion neurones; Harmaline; Harmane; Rat; Voltage gated calcium currents; Voltage gated potassium currents; Voltage gated sodium currents

Indexed keywords

BETA CARBOLINE DERIVATIVE; HARMALINE; HARMAN; NEUROPROTECTIVE AGENT; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED POTASSIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL;

ADOLESCENT; ANIMAL CELL; ARTICLE; CALCIUM CURRENT; CALCIUM HOMEOSTASIS; CONTROLLED STUDY; DEPOLARIZATION; DRUG EFFECT; DRUG MECHANISM; IN VITRO STUDY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; RAT; SPINAL GANGLION; STEADY STATE;

ANIMALS; CALCIUM CHANNELS; CENTRAL NERVOUS SYSTEM STIMULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GANGLIA, SPINAL; HARMALINE; HARMINE; INHIBITORY CONCENTRATION 50; ION CHANNEL GATING; NEURONS, AFFERENT; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNELS; RATS; RATS, WISTAR; SODIUM CHANNELS; TIME FACTORS;

EID: 13244269813     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706024     Document Type: Article

References (27)

1. ALBORES, R., NEAFSEY, E.J., DRUCKER, G, FIELDS, J.Z. & COLLINS, M.A. (1990). Mitochondrial respiratory inhibition by N-methylated beta-carboline derivatives structurally resembling N-methyl-4-phenylpyridine. Proc. Natl. Acad. Sc. U.S.A., 87, 9368-9372.
2. ANDERSON, N.J., ROBINSON, E.S., HUSBANDS, S.M., DELAGRANGE, P., NUTT, D.J. & HUDSON, A.L. (2003). Characterization of [(3)H]harmane binding to rat whole brain membranes. Ann. N. Y. Acad. Sci., 1009, 175-179.
3. BONNET, U., LENIGER, T. & WIEMANN, M. (2000). Moclobemide reduces intracellular pH and neuronal activity CA3 neurones in guinea-pig hippocampal slices - implication for its neuroprotective properties. Neuropharmacology, 39, 2067-2074.
4. CARPENTIER, R.G. (1982). Effects of harmala alkaloids on transmembrane potentials of guinea-pig papillary muscles. Br. J. Pharmacol., 75, 207-212.
5. COBUZZI JR, R.J., NEAFSEY, E.J. & COLLINS, M.A. (1994). Differential cytotoxicities of N-methyl-beta-carbolinium analogues of MPP+ in PC12 cells: insights into potential neurotoxicants in Parkinson's disease. J. Neurochem., 62, 1503-1510.
6. FOX, A.P., NOWYCKY, M.C. & TSIEN, R.W. (1987). Single-channel recordings of three types of calcium channels in chick sensory neurons. J. Physiol., 394, 173-200.
7. GLENNON, R.A., DUKAT, M., GRELLA, B., HONG, S., COSTANTINO, L., TEITLER, M., SMITH, C., EGAN, C., DAVIS, K. & MATTSON, M.V. (2000). Binding of beta-carbolines and related agents at serotonin (5-HT(2) and 5-HT(1A)), dopamine (D(2)) and benzodiazepine receptors. Drug Alcohol Depend., 60, 121-132.
8. HAN, O.J., JOE, K.H., KIM, S.W., LEE, H.S., KWON, N.S., BAEK, K.J. & YUN, H.Y. (2001). Involvement of p38 mitogen-activated protein kinase and apoptosis signal-regulating kinase-1 in nitric oxide-induced cell death in PC12 cells. Neurochem. Res., 26, 525-532.
9. HILLE, B. (1992). Ionic Channels of Excitable Membranes, 2nd edn. Sunderland: Sinauer Associates Inc..
10. HUDSON, A.L., GOUGH, R., TYACKE, R., LIONE, L., LALIES, M., LEWIS, J., HUSBANDS, S., KNIGHT, P., MURRAY, F., HUTSON, P. & NUTT, D.J. (1999). Novel selective compounds for the investigation of imidazoline receptors. Ann N. Y. Acad. Sci., 881, 81-91.
11. IGELMUND, P., ZHAO, Y.Q. & HEINEMANN, U. (1996). Effects of T-type, L-type, N-type, P-type, and Q-type calcium channel blockers on stimulus-induced pre- and postsynaptic calcium fluxes in rat hippocampal slices. Exp. Brain Res., 109, 22-32.
12. KIM, D.H., JANG, Y.Y., HAN, E.S. & LEE, C.S. (2001). Protective effect of harmaline and harmalol against dopamine- and 6-hydroxydopamine-induced oxidative damage of brain mitochondria and synaptosomes, and viability loss of PC12 cells. Eur. J. Neurosci., 13, 1861-1872.
13. KUHN, W., MULLER, T., GERLACH, M., SOFIC, E., FUCHS, G., HEYE, N., PRAUTSCH, R. & PRZUNTEK, H. (1996). Depression in Parkinson's disease: biogenic amines in CSF of 'de novo' patients. J. Neural Transm., 103, 1441-1445.
14. LEE, C.S., HAN, E.S., JANG, Y.Y., HAN, J.H., HA, H.W. & KIM, D.E. (2000). Protective effect of harmalol and harmaline on MPTP neurotoxicity in the mouse and dopamine-induced damage of brain mitochondria and PC12 cells. J. Neurochem., 75, 521-531.
15. LOUIS, E.D., ZHENG, W., JUREWICZ, E.C., WATNER, D., CHEN, J., FACTOR-LITVAK, P. & PARIDES, M. (2002). Elevation of blood beta-carboline alkaloids in essential tremor. Neurology, 59, 1940-1944.
16. MAKER, P. & DAVIS, J.B. (1996). The role of monoamine metabolism in oxidative glutamate toxicity. J. Neurosci., 16, 6394-6401.
17. MAY, T., GREUBE, A., STRAUSS, S., HEINEKE, D., LEHMANN, J. & ROMMELSPACHER, H. (1994). Comparison of the in vitro binding characteristics of the beta-carbolines harmane and norharmane in rat brain and liver and in bovine adrenal medulla. Naunyn-Sckmiedeberg's Arch. Pharmacol., 349, 308-317.
18. MCCORMICK, S.J. & TUNNICLIFF, G. (1998). Inhibitors of synaptosomal gamma-hydroxybutyrate transport. Pharmacology, 57, 124-131.
19. O'HEARN, E. & MOLLIVER, M.E. (1993). Degeneration of Purkinje cells in parasagittal zones of the cerebellar vermis after treatment with ibogaine or harmaline. Neuroscience, 55, 303-310.
20. PRZEDBORSKI, S. & JACKSON-LEWIS, V. (1998). Experimental developments in movement disorders: update on proposed free radical mechanisms. Curr. Opin. Neurol., 11, 338-339.
21. ROMMELSPACHER, H., NANZ, C., BORBE, H.O., FEHSKE, K.J., MULLER, W.E. & WOLLERT, U. (1980). 1-Methyl-beta-carboline (harmane), a potent endogenous inhibitor of benzodiazepine receptor binding. Naunyn-Schmiedeberg's Arch. Pharmacol., 314, 97-100.
22. ROMMELSPACHER, H., SCHMIDT, L.G. & MAY, T. (1991). Plasma norharman (beta-carboline) levels are elevated in chronic alcoholics. Alcohol. Clin. Exp. Res., 15, 553-559.
23. SHI, C.C., CHEN, S.Y., WANG, G.J., LIAO, J.F. & CHEN, C.F. (2000). Vasorelaxant effect of harmane. Eur. J. Pharmacol., 390, 319-325.
24. SHI, C.C., LIAO, J.F. & CHEN, C.F. (2001). Spasmolytic effects of three harmala alkaloids on guinea-pig isolated trachea. Pharmacol. Toxicol., 89, 259-264.
25. SPIJKERMAN, R., VAN DEN EIJNDEN, R., VAN DE MHEEN, D., BONGERS, I. & FEKKES, D. (2002). The impact of smoking and drinking on plasma levels of norharman. Eur. Neuropharmacol., 12, 61-71.
26. SPLETTSTOESSER, F., BONNET, U., WIEMANN, M., BINGMANN, D. & BÜSSELBERG, D. (2003). Modulation of voltage gated channel currents by harman and harmaline. Proc. Neurosci., 766.2.
27. STOHLER, R., HUG, I., KNOLL, B., MOHLER, B. & LADEWIG, D. (1996). Initial results with withdrawal treatments of male and female participants in the diversified Janus opiate prescription project in Basel. Schweiz. Rundsch. Med. Prax., 48, 1537-1541.